Lower volumes along with less number of new launches slowed the growth of the Indian Pharmaceutical Market (IPM) in December 2021 on a sequential basis.
According to India Ratings and Research (Ind-Ra), IPM continued to register slower growth of 5.3% YoY in December 2021 after growing 6.6% in November 2021.
“The acute therapy segment performed in line with the subchronic and chronic segments in December 2021,” the rating agency said.
As a result, Ind-Ra pointed out that the acute segment has been showing robust performance since March 2021.
“After the normalization of the strong growth months of April 2021 and May 2021, driven by the lower base linked to the lockdown last year and higher volume growth, the average MPI growth from June to December 2021 was healthy.
“In terms of growth drivers, price growth, new product launch growth, and volume growth were 5.6%, 2.9%, and 6.4% year-on-year, respectively, in moving annual total price, which led to an overall MPI size of Rs 1,671 billion in December 2021,” he said.
According to the agency, the acute therapy segment recorded sales growth of 5.3% year-on-year, while the chronic and subchronic therapy segments recorded growth of 4.8% and 6%, respectively. , in December 2021.
“In FY21, Ind-Ra highlights that the acute therapy segment experienced negative growth due to Covid-19, while the chronic therapy segment experienced an average growth of 7% during of the same period.”
(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)